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Abstract
Importance
The loss of vision following Boston Keratoprosthesis (BKPro) surgery due to glaucoma
occurs at a high frequency as diagnosis and management of glaucoma after this procedure
pose challenges.
Objective
To compare visual outcomes in patients undergoing Boston Keratoprosthesis surgery with
and without prior or concurrent glaucoma surgery.
Design, setting, and participants
This is a retrospective, observational cohort study of patients who underwent Boston Type I
Keratoprosthesis surgery. 19 eyes of 18 patients who had undergone BKPro and met the
inclusion criteria were identified. Twelve eyes received BKPro with prior or concurrent glau-
coma surgery (Group 1), and seven eyes were identified undergoing BKPro surgery without
prior or concurrent glaucoma surgery (Group 2).
Main outcomes and measures
Main outcome included best corrected visual acuity at each follow up.
Results
In Group 1, mean best corrected visual acuity (BCVA) within a year of BKPro surgery
was 20/100 (range 20/40 to Count Fingers (CF); n = 12) and mean BCVA at 1 year from
BKPro surgery was 20/115 (range 20/30 to CF; n = 12). 7 out of 12 patients retained or had
improved BCVA at 1 year follow up after BKPro implantation, and 5 out of 12 patients had
mild BCVA worsening. In Group 2, the mean BCVA within a year of BKPro surgery was 20/
140 (ranging from 20/25 to hand motion vision (HM); n = 7) and mean BCVA at 1 year from
BKPro surgery was Count Fingers (range 20/60 to Light Perception (LP); n = 6). 4 out of 6
patients lost significant vision at one year after BKPro.
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Conclusions and relevance
BKPro patients with early glaucoma surgical intervention retained vision significantly better
compared to patients with late or no intervention. Our preliminary findings support the rec-
ommendation for concurrent or pre-emptive glaucoma surgical intervention in patients
undergoing BKPro implantation.
Introduction
The restoration of a clear visual axis in patients who suffer from corneal blindness can present
challenges in those who are also poor candidates for traditional corneal transplantation tech-
niques. These patients often have failed multiple prior penetrating keratoplasties, have ocular
surface scarring due to trauma or autoimmune disease, and/or have limbal stem cell deficien-
cies. The Boston Keratoprosthesis (BKPro) is a prosthetic corneal device that offers an option
to restore vision in this cohort of patients. The initial technique was FDA approved for use in
1992 and has evolved to reduce many of the initial shortcomings. This has resulted in more fre-
quent use and greater success in restoring vision in those who are poor candidates for pene-
trating keratoplasty.
The design of the BKPro consists of 3 main components. There is a corneal graft, which is
enveloped between a central optical polymethyl methacrylate (PMMA) button and a posterior
plate. This design allows a fixed clear central visual axis with peripheral corneal graft tectonic
support to suture to the globe. Although surgeon experience has resulted in improved out-
comes and more successful adoption of this technique, there remain several frequently
encountered post-operative challenges. These challenges include the development of retro-
prosthetic membranes [1], a high incidence of endophthalmitis [2] and a significant rate of
vision loss from uncontrolled glaucoma [3–5]. Lifelong topical antibiotic prophylaxis and
YAG laser membranectomy can be used to address the former two concerns, but the latter has
remained a challenge. The typical mechanism of this glaucoma is the synechial closure of the
angle following repeat corneal transplantation [6]. Many of these patients have pre-existing
angle closure form prior penetrating keratoplasty in addition to ultrastructural changes to any
remaining accessible trabecular meshwork tissue from chronic topical steroid usage.
Patients undergoing traditional penetrating keratoplasty are already at increased risk of
developing glaucoma due to angle closure or as a result of steroid induced elevation of intraoc-
ular pressure. Traditionally, glaucoma after penetrating keratoplasty can be identified through
measurement of intraocular pressure and measurement of visual field and treated with tradi-
tional methods such as topical medications or glaucoma filtering surgery. Patients undergoing
prosthetic corneal transplantation with BKPro may be at the same or greater risk of developing
glaucomatous disease after surgery [3–5], however diagnosis and treatment can be a much
greater challenge. The most common methods of intraocular pressure (IOP) measurement are
dependent on the biomechanical properties of human corneal tissue. After BKPro, however,
the replacement of host or human graft cornea with the central corneal button PMMA mate-
rial precludes accurate IOP measurement. Examiners currently estimate IOP by digital scleral
or trans-palpebral palpation, which are notoriously unreliable.
Due to this imprecise measurement of IOP, many patients who do develop glaucoma
after BKPro suffer glaucomatous vision loss as a result of delayed diagnosis. Even when ele-
vated IOP is identified postoperatively, the success of topical medications in lowering IOP is
challenging to assess and other traditional methods of glaucoma monitoring such as visual
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field testing and optic nerve imaging are not reliable. Furthermore, should glaucoma sur-
gery be indicated after BKPro, the anatomical restrictions from limited anterior chamber
visualization make it preferable to adopt a pars plana implantation of a glaucoma filtering
implant with pars plana vitrectomy. Given the frequency of vision loss after BKPro, glau-
coma surgery may be of benefit when planned concurrently with BKPro as a measure to pre-
vent vision loss from uncontrolled IOP. In this study, we aim to investigate the relationship
between vision retention and early versus late surgical glaucoma intervention in patients
with type 1 Bkpro.
Methods
This is a retrospective, observational cohort study of all patients who underwent Boston
Type I Keratoprosthesis surgery between the dates of January 1, 2006 through December 31,
2016 at the University of California, Irvine Ophthalmology Clinic (Orange, CA) and Gavin
Herbert Eye Institute (Irvine, CA). All Boston type I Keratoprothesis were performed by a
single surgeon and identified using CPT codes for Keratoprosthesis surgery. Institutional
Review Board Approval at UC Irvine was obtained for this review, and a waiver for patient
consent was granted as this was a retrospective review. 34 eyes of 22 patients were initially
identified who had undergone BKPro. A minimum of six months of follow-up was required
for inclusion in the study. Eyes that required repeated BKPro, retinal detachment repair, or
enucleation during the follow-up period were excluded from the study. Additionally, eyes
that had severe retroprosthetic membrane formation, stromal melt, or infectious keratitis
that required explanation of BKPro or placement of a new BKPro during the follow-up
period were excluded. After applying inclusion and exclusion criteria, 19 eyes of 18 patients
were included in this review, and were separated into two groups. Group 1 underwent glau-
coma surgery at the time of BKPro or within 3 months of BKPro, and the other group either
did not undergo glaucoma surgery or underwent surgery later than 3 months postopera-
tively. Primary outcome was BCVA at 6 (± 1) months, 12 (± 2) months, 24 (± 2) months, and
36 (± 2) months post-BKPro. BCVA following visual acuity stabilization within 12 months
post-BKPro was also measured. Visual Acuity was initially measured with the Snellen chart
then converted to a continuous Logarithm of the Minimal Angle of Resolution (Log MAR)
units for quantitative analysis. For non-numerical values, the conversions are as follows:
Count Fingers = 1.7, Hand Motion = 2.0, Light Perception = 2.3, and No Light Perception
(NLP) = 3.0. Each patient’s age, gender, previous surgeries, pre-operative number of glau-
coma medications and pre-operative IOP, as measured with applanation or indentation
tonometry, were recorded as part of baseline characteristics (Table 1). Original dataset is
provided as supporting information (S1 Table).
Reliable visual fields, optic disc imaging, retinal nerve fiber layer analysis, or objective post-
op IOP measurements were unavailable for each patient at consistent time points post-opera-
tively to be meaningfully compared between the groups, and thus were not reported.
Continuous variables were expressed and tabulated as mean values with corresponding
standard deviations. Standard error of mean was represented in graphical form. Categorical
values were expressed as discrete integers, frequencies, and/or percentages. Comparison of
baseline characteristic means between the two groups was achieved with independent Stu-
dent’s t-test assuming unequal variance, and comparison of mean visual acuity in LogMAR
was achieved with the Mann-Whitney U nonparametric test. Differences among categorical
values between the groups were assessed using Fisher’s exact test (2-tailed). Statistical signifi-
cance was defined as p< 0.05 for all tests.
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Results
Nineteen eyes of 18 patients who underwent Boston Type I Keratoprosthesis implantation
meeting the inclusion criteria were identified. Of these 19 eyes in the study, there were no doc-
umented cases of endophthalmitis or vitritis during the follow-up period. Twelve eyes of 11
patients received prior glaucoma surgery (n = 8) or glaucoma drainage implants concurrently
(n = 4) with BKPro (Group 1). Of the remaining seven eyes in seven patients, six had never
received any glaucoma surgery, and one patient received glaucoma surgery 2.5 year after
BKPro (Group 2). Of note, two patients in Group 2 received cyclophotocoagulation six months
and two years after BKPro, respectively. Table 1 summarizes baseline characteristics of the
eyes included in the study. The mean age at time of BKPro implantation for Group 1 was 53.3
years (range of 31–81) versus 60.1 years (range 39–80) for Group 2. All eyes had previous cor-
neal graft failures or failed BKPro prior to BKPro implantation, with the most common reason
for initial corneal surgery being ocular trauma (four of twelve eyes) for Group 1, and chemical
injury (three of seven eyes) for Group 2. At the start of study period, 10 of 12 eyes in Group 1
had first time BKPro surgeries, versus five of seven eyes in Group 2. Ten of 12 patients in
Group 1 had glaucoma medication use prior to BKPro (mean number of glaucoma
Table 1. Baseline characteristics of patients with Boston type I Keratoprosthesis with or without prior or concurrent glaucoma surgical
intervention.
Group 1 (n = 12) Group 2 (n = 7) p-value*
Baseline Demographics†
Mean Age (year ± SD) at time of Kpro 53.3 ± 19.3 60.1 ± 15.4 0.41
Female Gender, no. (%) 4/11 (36%) 3/7 (43%) 1.00
Mean follow-up time (month ± SD) 38.0 ± 16.0 51.4 ± 15.0 0.09
Indication for Kpro surgery
Graft/KPro failure 12 (100%) 7 (100%)
Steven-Johnson Syndrome, no. (%) 2 (17%) 2 (29%) 0.60
Chemical Injury, no. (%) 1 (8%) 3 (43%) 0.12
Corneal Decompensation, no. (%) 2 (17%) 1 (14%) 1.00
Aniridia, no. (%) 2 (17%) 0 0.51
Infectious Keratitis, no. (%) 1 (8%) 1 (14%) 1.00
Trauma, no. (%) 4 (33%) 0 0.25
Initial Kpro surgery‡, no. (%) 10 (83%) 5 (71%) 0.60
Preoperative glaucoma history
Mean IOP (mmHg ± SD) 15.6 ± 5.3 15.4 ± 3.8 0.62
History of glaucoma medications, no. (%) 10 (83%) 5 (71%) 0.60
Mean number of glaucoma medications ± SD 2.3 ± 1.8 1.3 ± 1.5 0.27
Prior glaucoma surgery
Trabeculectomy, no. (%) 2 (17%) -
Glaucoma drainage implant, no. (%) 7 (58%) -
Concurrent glaucoma drainage implant, no. (%) 4 (33%) -
* Fisher exact test used to compare categorical variables between Group 1 and Group 2; Students t-test used to compare mean values between Group 1
and Group 2 assuming unequal variance. Statistical significance is defined as p < 0.05.
† values calculated per patient (11 in group 1 and six in group 2).
‡ denotes number of eyes that did not receive prior Kpro surgeries.
Kpro = Boston type I Keratoprosthesis; Group 1 = patients who had glaucoma surgery prior to or concurrently with Kpro; Group 2 = patients with no history
of glaucoma surgery or after 3 months post-Kpro; n = number of eyes; SD = standard deviation.
https://doi.org/10.1371/journal.pone.0182190.t001
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medications = 2.3) versus five of seven patients in Group 2 (mean number of glaucoma medi-
cations = 1.3). Mean follow-up time was 38 months for Group 1, and 51 months for Group 2.
Preoperative best corrected visual acuity (BCVA) ranged from 20/400 to HM for both
groups (with the median being CF in both), with an average LogMAR of 1.76 ± 0.26 for Group
1 and 1.81 ± 0.27 for Group 2 (p = 0.65). All patients had retained or improved BCVA within 3
months after BKPro (median 20/150 in Group 1 and 20/400 in group 2). Mean BCVA before
and after BKPro at several time points are displayed in Fig 1. BCVA was retained better in
Group 1 throughout the post-operatively course, but with only the 12-month timepoint reach-
ing statistical significance (p = 0.028).
Loss of vision, as defined by the difference in LogMAR between best corrected vision after
stabilization within 12 months and best corrected vision at 12, 24, and 36 months post-BKPro
are shown in Table 2. Average BCVA within 12 months was 20/100 for Group 1 (range 20/30
to count fingers) and 20/140 (range 20/25 to HM) for Group 2. At the 12 months post-opera-
tive visits, vision loss in Group 1 was statistically significantly lower compared to Group 2
(p = 0.027), and at later follow-ups Group 1 had consistently lower BCVA loss, however there
is no statistical difference.
Breakdowns of BCVA by each individual eye within 1 year post-BKPro and then at 1 year
are shown in Fig 2. Four out of six eyes in Group 2 had significant worsening of vision at 1
year, and the two eyes that retained their BCVA had unchanged BCVA of 20/400 and HM
Fig 1. Mean best corrected visual acuity (BCVA) before Keratoprosthesis (pre-Kpro) and at several time points post-KPro
implantation for patients with or without prior or concurrent glaucoma surgical intervention. Group 1 = patients who had glaucoma
surgery prior to or concurrently with Kpro; Group 2 = patients with no history of glaucoma surgery or surgery3 months post-Kpro. P-values
calculated with Mann-Whitney U nonparametric t-test. n denotes number of eyes. Error bars represent Standard Error of the Mean.
Statistical significance is defined as p < 0.05.
https://doi.org/10.1371/journal.pone.0182190.g001
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within 1 year. Five out of 12 eyes in Group 1 had decreased BCVA, three had unchanged
BCVA, and four had improved BCVA.
Discussion
The use of the BKPro to restore vision in corneal blindness has been a significant milestone in
therapy to offer to patients who previously had severely limited options for vision restoration.
Although initial adoption of this procedure was slow, it has been more frequently offered in
the last decade as surgeons have encountered better outcomes. Much of this success in improv-
ing outcomes using the BKPro procedure can be attributed to improved management of the
most common post-operative issues [7–9]. Retroprosthetic membranes, which can be recur-
rent, are treated successfully with YAG laser [1]. The rate of post-operative endophthalmitis
has been reduced with ongoing prophylactic topical antibiotic use [2]. Vision loss due to post-
operative uncontrolled eye pressure and glaucoma is still a problematic post-operative issue
for which a consensus approach is not widely used. Studying glaucoma in this population is
highly challenging due to inability to visualize the optic nerve before or after surgery in many
cases, and inability to test optic nerve function or structure. Furthermore, there is no standard-
ized or reliable method for measuring IOP after BKPro surgery beyond digital estimation.
This retrospective review demonstrates better visual acuity retention one-year post opera-
tively in patients who undergo glaucoma surgical intervention concurrently or close to the
time of BKPro surgery. What is also of equal importance is the incidence of significant vision
loss in the group of patients undergoing BKPro without close or concurrent glaucoma surgery.
Although there are limitations in the outcome measures and it is difficult to accurately ascer-
tain all causes of BCVA loss following BKPro, these results may suggest a trend of worsening
vision loss over time when glaucoma is not prophylactically addressed at the time of BKPro
surgery.
Surgeons have reached a consensus in measures to reduce the impact of retroprosthetic
membranes and endophthalmitis after BKPro. Perhaps anticipating the need for glaucoma
surgery at the time of BKPro can reduce the impact of vision loss from glaucoma post opera-
tively. The way in which glaucoma surgery can be offered with BKPro requires careful consid-
eration. Given the limitations in visualizing the peripheral anterior chamber after BKPro and
the higher rates of postoperative infection, standard approaches to external filtration surgery
are difficult. A trabeculectomy bleb may increase the lifetime risk of infection in an eye already
prone to endophthalmitis, and placement of a tube into the anterior chamber or sulcus is pre-
cluded without the necessary visualization. In the past, authors have employed cyclodestructive
Table 2. Vision loss, as determined by LogMAR of BCVA at several time points minus BCVA within 12 months post-Kpro, for patients with or with-
out prior or concurrent glaucoma surgical intervention.
Vision Loss from Post-KPro BCVA within 12 months
Group 1 LogMAR ± SD, (n) Group 2 LogMAR ± SD, (n) p-value*
post-Kpro 12 months -0.03 ± 0.02 (12) -0.69 ± 0.36 (6) 0.027
post-Kpro 24 months -0.10 ± 0.04 (10) -0.54 ± 0.74 (6) 0.811
post-Kpro 36 months -0.24 ± 0.07 (10) -0.67 ± 0.99 (6) 1.000
*Mann-Whitney U nonparametric t-test used to compare mean BCVA between Group 1 and Group 2.
LogMAR = logarithm of minimum angle of resolution; SD = standard deviation; n = number of eyes.
Group 1 = patients who had glaucoma surgery prior to or concurrently with Kpro;
Group 2 = patients with no history of glaucoma surgery or 3 months post-Kpro.
Statistical significance is defined as p < 0.05.
https://doi.org/10.1371/journal.pone.0182190.t002
Vision retention in early versus delayed glaucoma surgery in patients with Boston Keratoprosthesis type 1
PLOS ONE | https://doi.org/10.1371/journal.pone.0182190 August 4, 2017 6 / 9
Fig 2. Best corrected visual acuity (BCVA) for patients with or without prior or concurrent glaucoma surgical intervention within
12 months and at 12 months post-Kpro implantation. Individual lines on graphs correspond to individual eyes. Group 1 = patients who
had glaucoma surgery prior to or concurrently with Kpro; Group 2 = patients with no history of glaucoma surgery or 3 months post-Kpro.
https://doi.org/10.1371/journal.pone.0182190.g002
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procedures to be used in conjunction with the BKPro surgery with some success [10]. How-
ever, the inflammatory nature of cyclodestruction can possibly lead to rejection of a corneal
graft and, in some cases, lead to cystoid macular edema that can result in reduced BCVA. In
our review, the most common approach to glaucoma surgery at the time of BKPro was to use a
glaucoma implant with a pars plana insertion of the tube. Tube placement was made possible
by concurrent pars plana vitrectomy. This approach may offer the most predictable result in
pressure lowering while reducing the possible post-operative adverse events [11].
Even in patients who have successful coordination of glaucoma surgery at the time of
BKPro with stable BCVA over time, glaucoma has the potential to worsen and present as a
later complication to BCVA. Digital applanation, although a crude method even with expert
examiners, still offers some ability to gauge IOP when compared with the patient’s contralat-
eral eye where Goldmann applanation may be possible. In patients where BCVA and coopera-
tion allows serial visual field testing and optic nerve structural analysis, these tools may allow
for close monitoring and escalation of treatment as needed. In patients where these tools are
not possible, serial examination of the optic nerve head and comparison with baseline optic
nerve photos may be a useful tool. If IOP control is in doubt, escalation of treatment with topi-
cal glaucoma medications should be strongly considered.
There are numerous limitations to this study. Firstly, there is no way to directly identify
glaucoma as the main cause of vision loss in this group of subjects. While vision loss may be
secondary to numerous contributing causes, our study does correlate early surgical interven-
tion with better retention of vision. Secondly, this is a retrospective study with all the inherent
limitations therein. Also, the number of subjects is limited, particularly in the late-intervention
group. With a small sample size, adjustments based on age, gender, race, baseline IOP, or
comorbidities would not yield meaningful conclusions. We also acknowledge that since visual-
ization of the retina, optic nerve head, and measurement of IOP are challenging in these
patients, comorbidities and complications such as retinal pathologies, suprachoroidal hemor-
rhage, and hypotony maculopathy cannot be consistently elicited and reliably gathered
from all patient’s charts. These factors may confound visual acuity post-operatively. Lastly,
selection bias may exist for patients with worse glaucomatous disease at baseline to undergo
concurrent intervention. If such bias confounds our findings, however, they would likely
further strengthen the relationship between early intervention and improved visual acuity
outcomes.
In summary, we observed increased vision retention at 12 months post-op for patients
who underwent early or concurrent glaucoma surgery with BKPro compared to patients who
received late or no glaucoma surgery. Our findings suggest that prophylactic glaucoma surgery
may be beneficial for patients undergoing K-pro implantation. Larger-scale prospective studies
are needed to confirm the strength of this relationship and further characterize the complica-
tion profiles versus clinical benefit of concurrent glaucoma surgery with K-pro.
Supporting information
S1 Table. Original dataset containing matrix of patient’s visual acuity and intraocular
pressure measurements at various timepoints.
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